BCL10
BCL10 (B-cell lymphoma/leukaemia 10) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Lung cancer, Diffuse large B-cell lymphoma and 1 more.
Overview
Plays a key role in both adaptive and innate immune signalling by bridging CARD domain-containing proteins to immune activation. Acts by channeling adaptive and innate immune signalling downstream of CARD domain-containing proteins CARD9, CARD11 and CARD14 to activate NF-kappa-B and MAP kinase p38 (MAPK11, MAPK12, MAPK13 and/or MAPK14) pathways which stimulate expression of genes encoding pro-inflammatory cytokines and chemokines. Recruited by activated CARD domain-containing proteins: homooligomerised CARD domain-containing proteins form a nucleating helical template that recruits BCL10 via CARD-CARD interaction, thereby promoting polymerisation of BCL10, subsequent recruitment of MALT1 and formation of a CBM complex.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.69 (direct and indirect evidence; datatypes literature 0.80, genetic association 0.19, somatic mutation 0.88). IntOGen calls it a driver in 3 cohorts (1 activating, 2 loss-of-function), covering Diffuse Large B-Cell Lymphoma, NOS, Malignant Lymphoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · BCL10 (B-cell lymphoma/leukaemia 10) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Lung cancer, Diffuse large B-cell lymphoma and 1 more.
- 1 · What it is
BCL10 (B-cell lymphoma/leukaemia 10) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Lung cancer, Diffuse large B-cell lymphoma and 1 more.
- 2 · What goes wrong in cancer
Plays a key role in both adaptive and innate immune signalling by bridging CARD domain-containing proteins to immune activation.
- 3 · How drugs use it
No product in this corpus aims at BCL10 yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
External identifiers
Sources: HGNC HGNC:989 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt O95999 (protein name, function text, keywords and locations (REST API)); CIViC gene BCL10 (1 evidence items, 0 assertions, 1 variants; diseases: Diffuse Large B-cell Lymphoma (GraphQL API, CC0)); Open Targets ENSG00000142867 (association with cancer (MONDO_0004992) 0.69; per-cancer scores at or above 0.5: diffuse large B-cell lymphoma 0.54, non-Hodgkin lymphoma 0.71, lung cancer 0.50, marginal zone lymphoma 0.58 (GraphQL API, CC0)); IntOGen BCL10 (driver in 3 cohorts (Act 1, LoF 2); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Plays a key role in both adaptive and innate immune signalling by bridging CARD domain-containing proteins to immune activation. Acts by channeling adaptive and innate immune signalling downstream of CARD domain-containing proteins CARD9, CARD11 and CARD14 to activate NF-kappa-B and MAP kinase p38 (MAPK11, MAPK12, MAPK13 and/or MAPK14) pathways which stimulate expression of genes encoding pro-inflammatory cytokines and chemokines. Recruited by activated CARD domain-containing proteins: homooligomerised CARD domain-containing proteins form a nucleating helical template that recruits BCL10 via CARD-CARD interaction, thereby promoting polymerisation of BCL10, subsequent recruitment of MALT1 and formation of a CBM complex. This leads to activation of NF-kappa-B and MAP kinase p38 (MAPK11, MAPK12, MAPK13 and/or MAPK14) pathways which stimulate expression of genes encoding pro-inflammatory cytokines and chemokines. Activated by CARD9 downstream of C-type lectin receptors; CARD9-mediated signals are essential for antifungal immunity. Activated by CARD11 downstream of T-cell receptor (TCR) and B-cell receptor (BCR). Location: Cytoplasm, perinuclear region; Membrane raft (UniProt). Locus 1p22.3 (HGNC).
- Non-Hodgkin lymphoma: Open Targets association 0.71 with non-Hodgkin lymphoma (MONDO_0018908); IntOGen driver in 1 cohort (MLYM)
- Lung cancer: Open Targets association 0.50 with lung cancer (MONDO_0008903)
- Diffuse large B-cell lymphoma: Open Targets association 0.54 with diffuse large B-cell lymphoma (MONDO_0018905); CIViC evidence names this disease
- Marginal zone lymphoma: Open Targets association 0.58 with marginal zone lymphoma (MONDO_0017604)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 1 cohort; IntOGen calls it a loss-of-function (LoF) driver in 2 cohorts; CIViC holds 1 clinical evidence items on its variants; UniProt disease notes describe a translocation or gene fusion involving the gene. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"BCL10" OR ABSTRACT:"BCL10" OR TITLE:"BCL10 immune signaling adaptor" OR ABSTRACT:"BCL10 immune signaling adaptor" OR TITLE:"B-cell lymphoma/leukemia 10" OR ABSTRACT:"B-cell lymphoma/leukemia 10" OR TITLE:"CARMEN" OR ABSTRACT:"CARMEN" OR TITLE:"CIPER" OR ABSTRACT:"CIPER" OR TITLE:"mE10" OR ABSTRACT:"mE10") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about BCL10, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetTNFRSF14
Shares Lung cancer (all types), Non-Hodgkin lymphoma (all types), CIViC, Diffuse large B-cell lymphoma.
- TargetTNFAIP3
Shares Marginal zone lymphoma, Non-Hodgkin lymphoma (all types), CIViC, Diffuse large B-cell lymphoma.
- TargetP2RY8
Shares Lung cancer (all types), Non-Hodgkin lymphoma (all types), CIViC, Diffuse large B-cell lymphoma.
- TargetBCL6
Shares Lung cancer (all types), Non-Hodgkin lymphoma (all types), CIViC, Diffuse large B-cell lymphoma.
- TargetPOU2AF1
Shares Lung cancer (all types), Non-Hodgkin lymphoma (all types), CIViC, Diffuse large B-cell lymphoma.
- TargetMALT1
Shares B-cell receptor / BTK signalling (to NF-κB), Diffuse large B-cell lymphoma, IntOGen, Open Targets Platform.
- TargetCIITA
Shares Lung cancer (all types), Non-Hodgkin lymphoma (all types), CIViC, Diffuse large B-cell lymphoma.
- TargetCARD11
Shares B-cell receptor / BTK signalling (to NF-κB), Lung cancer (all types), Non-Hodgkin lymphoma (all types), CIViC.